Get the Stockscreener App
8.50
2.91%
0.24
After Hours:
8.67
0.17
+2.00%
Engene Holdings Inc stock is traded at $8.50, with a volume of 188.39K.
It is up +2.91% in the last 24 hours and up +5.33% over the past month.
enGene Holdings Inc is a clinical-stage biotechnology company mainstreaming genetic medicine through the delivery of therapeutics to mucosal tissues and other organs, with the goal of creating new ways to address diseases with high clinical needs, beginning with non-muscle invasive bladder cancer (NMIBC). The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
See More
Previous Close:
$8.26
Open:
$8.36
24h Volume:
188.39K
Relative Volume:
0.16
Market Cap:
$569.37M
Revenue:
-
Net Income/Loss:
$-103.21M
P/E Ratio:
-1.8478
EPS:
-4.6001
Net Cash Flow:
$-26.70M
1W Performance:
-5.87%
1M Performance:
+5.33%
6M Performance:
+123.10%
1Y Performance:
+9.54%
1-Day Range:
$8.30
$9.04
1-Week Range:
$8.17
$9.10
52-Week Range:
$2.65
$11.14
Engene Holdings Inc Stock (ENGN) Company Profile
Name
Engene Holdings Inc
Sector
Industry
Phone
(514) 332-4888
Address
4868 RUE LEVY, SUITE 220, SAINT-LAURENT
Compare ENGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENGN
Engene Holdings Inc
|
8.50 | 553.29M | 0 | -103.21M | -26.70M | -4.6001 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Engene Holdings Inc Stock (ENGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-25 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-18-25 | Initiated | Piper Sandler | Overweight |
| Feb-14-25 | Downgrade | UBS | Buy → Neutral |
| Dec-23-24 | Initiated | H.C. Wainwright | Buy |
| Nov-27-24 | Initiated | Raymond James | Outperform |
| Nov-18-24 | Initiated | JMP Securities | Mkt Outperform |
| Aug-28-24 | Initiated | Oppenheimer | Outperform |
| Apr-22-24 | Initiated | Wells Fargo | Overweight |
| Apr-15-24 | Initiated | Guggenheim | Buy |
| Mar-28-24 | Initiated | UBS | Buy |
| Mar-08-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | Leerink Partners | Outperform |
View All
Engene Holdings Inc Stock (ENGN) Latest News
enGene Holdings Inc Stock Analysis and ForecastValue Traps to Avoid & Hidden Gems with Outstanding Profit Margins - earlytimes.in
Citizens reiterates Market Outperform rating on Engene stock with $21 target - Investing.com Canada
enGene (NASDAQ:ENGN) Shares Gap Up – Should You Buy? - Defense World
enGene (NASDAQ:ENGN) Shares Gap UpStill a Buy? - MarketBeat
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN) - Seeking Alpha
ETFs Investing in enGene Holdings Inc. Stocks - TradingView — Track All Markets
While Institutions Invested in EnGene Holdings Inc. (NASDAQ:ENGN) Benefited From Last Week's 21% Gain, Private Equity Firms Stood to Gain the Most - 富途牛牛
Analysts Offer Insights on Healthcare Companies: enGene Holdings (ENGN) and Agios Pharma (AGIO) - The Globe and Mail
HC Wainwright Forecasts enGene's Q1 Earnings (NASDAQ:ENGN) - MarketBeat
enGene (NASDAQ:ENGN) Sees Large Volume IncreaseHere's Why - MarketBeat
Engene stock remains a Buy at H.C. Wainwright on NMIBC treatment advantages By Investing.com - Investing.com South Africa
enGene (NASDAQ:ENGN) Trading Up 4.6%What's Next? - MarketBeat
Engene stock remains a Buy at H.C. Wainwright on NMIBC treatment advantages - Investing.com Nigeria
enGene Reports Full Year 2025 Financial Results and Provides Business Update - BioSpace
enGene completes enrollment in bladder cancer treatment trial - Investing.com India
enGene completes enrollment in bladder cancer treatment trial By Investing.com - Investing.com Nigeria
EnGene Fiscal 2025 Loss Widens - marketscreener.com
enGene (NASDAQ:ENGN) Announces Earnings Results - MarketBeat
enGene Holdings Inc. SEC 10-K Report - TradingView — Track All Markets
EnGene Holdings Inc. Reports Earnings Results for the Full Year Ended October 31, 2025 - marketscreener.com
enGene announces proposed public offering - MSN
Will enGene Holdings Inc. stock rally after Fed decisionsTrade Entry Report & Fast Exit and Entry Trade Guides - Улправда
Is enGene Holdings Inc. Equity Warrant stock a top pick in earnings season2025 Volume Leaders & Verified Swing Trading Watchlists - Улправда
Weekly Recap: Can enGene Holdings Inc. Equity Warrant stock attract ESG capital inflowsJuly 2025 Catalysts & Expert Curated Trade Setups - Улправда
Will enGene Holdings Inc. stock benefit from AI adoption2025 Market WrapUp & Long Hold Capital Preservation Tips - bolumsonucanavari.com
Valuation Update: Can enGene Holdings Inc. Equity Warrant stock attract ESG capital inflowsJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - Улправда
Is enGene Holdings Inc. Equity Warrant stock a good choice for value investorsWeekly Profit Recap & Fast Moving Trade Plans - Улправда
How enGene Holdings Inc. stock performs in stagflationJuly 2025 Decliners & AI Driven Price Forecasts - Улправда
How sustainable is enGene Holdings Inc. Equity Warrant stock dividend payout2025 Support & Resistance & Fast Entry High Yield Stock Tips - Улправда
Can enGene Holdings Inc. Equity Warrant stock attract ESG capital inflowsJuly 2025 Patterns & AI Powered Trade Plan Recommendations - Улправда
Is enGene Holdings Inc. Equity Warrant stock a dividend growth opportunityJuly 2025 Selloffs & Scalable Portfolio Growth Ideas - DonanımHaber
How enGene Holdings Inc. Equity Warrant stock performs in weak economyOil Prices & Weekly Setup with ROI Potential - DonanımHaber
How enGene Holdings Inc. stock performs in high volatility marketsPortfolio Update Report & Daily Volume Surge Signals - DonanımHaber
Insider Trends: Is enGene Holdings Inc. Equity Warrant stock a good choice for value investors2025 Technical Patterns & Safe Capital Growth Stock Tips - Улправда
Quarterly Risk: Is enGene Holdings Inc. Equity Warrant stock a top pick in earnings season2025 Earnings Impact & Weekly Return Optimization Alerts - Улправда
enGene Shares Gain 5% After Bladder Cancer Therapy Shows Stronger Response Rates - MSN
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
enGene Holdings Inc. (NASDAQ:ENGN) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
enGene (NASDAQ:ENGN) Shares Gap DownShould You Sell? - MarketBeat
enGene Holdings Inc trading resumes - MSN
enGene Holdings Amends CEO Severance Package - MSN
enGene (NASDAQ:ENGN) Stock Price Up 8.2%Time to Buy? - MarketBeat
enGene (ENGN) Projected to Post Earnings on Thursday - MarketBeat
Holdings of enGene Holdings Inc (ENGN) are aligned with the stars - setenews.com
EnGene Holdings Inc (ENGN) surging after positive phase 2 LEGEND trial - MSN
Market Recap: Can enGene Holdings Inc Equity Warrant stock attract ESG capital inflowsQuarterly Earnings Summary & Smart Money Movement Alerts - moha.gov.vn
enGene’s Detalimogene Chosen for FDA Manufacturing Pilot Program - TipRanks
enGene Holdings Inc (ENGN) Surging After Positive Phase 2 LEGEND Trial - Finviz
Engene Holdings Inc Stock (ENGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):